Incidence of nephrogenic systemic fibrosis after administration of gadoteric acid in patients on renal replacement treatment.
Adult
Aged
Biopsy
Contrast Media
/ adverse effects
Drug Hypersensitivity
/ etiology
Female
Gadolinium
/ adverse effects
Humans
Incidence
Kidney
/ drug effects
Magnetic Resonance Imaging
Male
Middle Aged
Nephrogenic Fibrosing Dermopathy
/ chemically induced
Prevalence
Renal Insufficiency, Chronic
/ complications
Retrospective Studies
Risk Factors
Rotation
Skin
/ pathology
Transplantation, Homologous
/ adverse effects
Gadolinium
Gadolinium contrast agent
Gadoteric acid
Nephrogenic systemic fibrosis
Renal replacement treatment
Journal
Magnetic resonance imaging
ISSN: 1873-5894
Titre abrégé: Magn Reson Imaging
Pays: Netherlands
ID NLM: 8214883
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
26
09
2019
revised:
20
02
2020
accepted:
21
02
2020
pubmed:
1
3
2020
medline:
1
12
2020
entrez:
1
3
2020
Statut:
ppublish
Résumé
Nephrogenic system fibrosis (NSF) is a rare complication detected in patients with renal insufficiency exposed to gadolinium-based contrast agents (GBCAs). The aim of our study is to evaluate the prevalence of NSF in a cohort of patients on renal replacement treatment who underwent GBCA-enhanced magnetic resonance imaging (MRI). We retrospectively reviewed all the charts of kidney transplant (KT) recipients, patients on hemodialysis (HD) and peritoneal dialysis (PD) who received a uniform protocol for contrast material enhanced-MRI with gadoteric acid at our center from January 2004 to December 2017. Three-hundred forty-four patients (44.1% on HD, 11.3% on PD and 44.4% KT recipients) underwent 551 gadoteric acid-enhanced MRI. The median age of the patients was 58 years (IQR, 45-70 years) and 65.1% were men. Sixty-three patients (18.3%) had skin punch biopsy after integumentary assessment performed by a dermatologist. No cases of NSF were detected after a median follow-up of 4.5 years (IQR, 1.9-8.2 years). During this period of observation, 116 (33.7%) patients died and 11 (3.1%) were lost at follow-up. None of the patients exposed to gadoteric acid developed NSF. Our results, in line with more recent studies, suggest that the use of gadoteric acid, a macrocyclic GBCA, appears safe even in chronic kidney disease (CKD) patients receiving dialysis.
Identifiants
pubmed: 32112811
pii: S0730-725X(19)30586-7
doi: 10.1016/j.mri.2020.02.012
pii:
doi:
Substances chimiques
Contrast Media
0
Gadolinium
AU0V1LM3JT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-4Informations de copyright
Copyright © 2020. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that there is no conflict of interest. The results presented in this paper have not been published previously in whole or part, except in abstract format.